Story perspectives

FDA Approves Otarmeni Gene Therapy, Free for Hearing Loss

4/24/2026

Summary

Story summary

FDA approved gene therapy Otarmeni for inherited hearing loss.
Regeneron will provide the therapy free to U.S. patients, unlike typical multi-million-dollar pricing, and will seek approval abroad without promising free provision.
The trial of 20 children showed 16 improved hearing, five of the 12 followed for at least 11 months reached normal hearing, and the surgery-like delivery was reported safe with only typical risks though patients may pay surgical costs.

1 of 1

Story summary

FDA approved gene therapy Otarmeni for inherited hearing loss.
Regeneron will provide the therapy free to U.S. patients, unlike typical multi-million-dollar pricing, and will seek approval abroad without promising free provision.
The trial of 20 children showed 16 improved hearing, five of the 12 followed for at least 11 months reached normal hearing, and the surgery-like delivery was reported safe with only typical risks though patients may pay surgical costs.